Filing Details
- Accession Number:
- 0001628280-24-027351
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2024-06-07 18:29:35
- Reporting Period:
- 2024-06-05
- Accepted Time:
- 2024-06-07 18:29:35
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1437402 | Ardelyx Inc. | ARDX | Pharmaceutical Preparations (2834) | 000000000 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1869194 | A Laura Williams | C/O Ardelyx, Inc. 400 Fifth Avenue, Suite 210 Waltham MA 02451 | Chief Medical Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2024-06-05 | 100,000 | $2.75 | 467,152 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2024-06-05 | 45,000 | $7.12 | 422,152 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2024-06-05 | 100,000 | $7.13 | 322,152 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Stock Option (Right to Buy) | Disposition | 2024-06-05 | 100,000 | $0.00 | 100,000 | $2.75 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 251,000 | 2033-01-05 | No | 4 | M | Direct |
Footnotes
- This transaction was executed in multiple trades in prices ranging from $7.11 to $7.145, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
- The option becomes exercisable as it vests and the shares subject to the option vest in 48 successive, equal monthly installments on each monthly anniversary of January 5, 2023, subject to the Reporting Person's continued employment or service relationship with the Issuer on each such vesting date.
Billionaire Hedge Funds
